RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Core Insights - RedHill Biopharma has entered into an exclusive worldwide licensing agreement with Hyloris Pharmaceuticals for RHB-102 (Bekinda®), which includes an upfront payment, potential milestone payments of up to $60 million, and mid-20s percent royalties on revenues for territories outside the U.S., Canada, and Mexico [1][2] - RHB-102 is positioned to be the first oral 24-hour extended-release ondansetron for treating chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV) if approved by the UK MHRA [1][4] - The global antiemetics drugs market was valued at approximately $7.5 billion in 2023 and is projected to grow at a CAGR of around 6% from 2024 to 2030 [5] Company Overview - RedHill Biopharma focuses on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, with key products including Talicia® for H. pylori infection [8] - Hyloris Pharmaceuticals specializes in innovating and optimizing existing medications to meet healthcare needs [7] Product Development - RHB-102 is a proprietary, once-daily, bimodal extended-release oral tablet formulation of ondansetron, targeting oncology support, acute gastroenteritis, gastritis, and diarrhea-predominant irritable bowel syndrome (IBS-D) at doses of 12 mg and 24 mg [3][6] - Positive results from U.S. Phase 2 and Phase 3 studies for RHB-102 have been published, indicating its efficacy in treating IBS-D and acute gastroenteritis [5][6]